Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dalpiciclib + letrozole + anlotinib
- Development stage
- Preclinical
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Dalpiciclib + letrozole + anlotinib is a combination regimen under investigation for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or early breast cancer. Dalpiciclib is a selective cyclin-dependent kinase 4/6 (CDK4/6) inhibitor that blocks cell cycle progression in tumor cells. Letrozole is a non-steroidal aromatase inhibitor that suppresses estrogen synthesis and is widely used as endocrine therapy in HR+ breast cancer. Anlotinib is a multi-targeted oral tyrosine kinase inhibitor with potent anti-angiogenic and anti-tumor activity; it inhibits vascular endothelial growth factor receptors (VEGFR) 2/3, fibroblast growth factor receptors (FGFR) 1–4, platelet-derived growth factor receptors (PDGFR) α/β, c-Kit and Ret[6][8]. This triple combination aims to simultaneously block cell proliferation pathways driven by CDK4/6 and estrogen signaling while inhibiting angiogenesis and additional tumorigenic pathways via multi-kinase inhibition.
- Other names
- dalpiciclib + letrozole + anlotinib
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)PDGFRA (Platelet-derived growth factor receptor alpha)KIT (c-KIT proto-oncogene receptor tyrosine kinase)CDK6 (Cyclin-dependent kinase 6)CYP19A1 (Aromatase)PDGFRB (Platelet-derived growth factor receptor beta)FGFR3 (Fibroblast growth factor receptor 3)CDK4 (Cyclin-dependent kinase 4)VEGFR3 (Vascular endothelial growth factor receptor 3)FGFR2 (Keratinocyte growth factor receptor)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on dalpiciclib + letrozole + anlotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dalpiciclib + letrozole + anlotinib.